Is Amygdalin Outcomes Weighing Detriments of Sorafenib Treatment In Female Mice With Kidney Injury Induced By Ehrlich Ascites Carcinoma Model? Preliminary study

Abstract

Aim: Nowadays, attention is intensifying in using natural sources of real antitumor agents that breed fewer side effects than unadventurous chemotherapeutic drugs. The Ehrlich ascites carcinoma (EAC) model is a spontaneous adenocarcinoma that can use to induce cancer in the targeted organ. This preliminary study is implemented to weigh the best choice for cancer treatment with fewer side effects and rule out the concomitant use of targeted drugs against kidney injury in female mice induced by EAC. Material and methods: The mice were apportioned into seven groups. The most affected parameters in the EAC mice model as Kidney functions and hematological parameters were measured. Furthermore, to exact unearth the values of two drugs, histopathological studies were further evaluated. Results: The results showed that the mice with EAC exhibited kidney functions with alterations of hematological parameters. Co-administration of vitamin B17 and sorafenib restored the kidney functions in serum. Ample histopathological variations were detected in kidney sections in EAC as marked damage and degenerated glomerular atrophy and necrosis of renal corpuscle and tubules. A moderate improvement in kidney sections noted in sorafenib (SOR) group as a mild degeneration in both renal corpuscles and renal tubules in addition to congestion of renal blood vessels were improved contrary to B17 group that improved better than SOR. Conclusion: It could be concluded that B17 has a potential defensive role against EAC cells-induced kidney toxicity rather than the undesirable effect of SOR in the tested parameters.